The second batch of national mining expiry contract renewals are open! These points need attention

In 2020, the renewal of the first batch of national bulk purchases has been completed. Most of the pilot cities follow the alliance's selected price. The alliance area mainly chooses to renew the contract with the original selected company at the original selected price. The exception is Hubei and the first is adopted. The post-competitive approach involves the introduction of newly-reviewed companies, and if the newly-reviewed companies are willing to participate, they will compete. After the introduction of other varieties of competition, the renewed products have indeed produced new low prices.Up to now, the country has completed four batches and five rounds. Almost each batch of centralized drug purchase prices has dropped by more than 50% on average, with the highest drop by more than 90%. The price of medicines has fallen so drastically, is the supply of medicines sustainable? In fact, you can look at the company's renewal after the expiration of the procurement contract, and see if the company is willing to continue to supply at the original price.The prices of the 4+7 pilot cities for contract renewal and alliance expansion and renewal have basically maintained their original prices. After individual provinces and cities set up new competition mechanisms, the selected prices have become lower than the original prices. So what is the situation of the second batch of volume purchase renewal? Will the price be further reduced on the basis of centralized procurement?According to industry news, the state will delegate the power to renew contracts to local governments for the varieties that have been collected by the state, and will take into account the changes in the competitive landscape brought about by the newly reviewed enterprises, and make specific arrangements. The overall guiding principle.If the power of contract renewal is delegated to the local area, there will be many differences in the rules of each province. There are many areas worthy of focus on the renewal of centralized procurement, which will directly affect the corresponding market competition pattern and the bidding strategy of related companies. , The following author will briefly review and analyze the key concerns about the rules.


1. Drug catalog and quality requirements for renewal


The quality requirements of drugs included in the national bulk procurement catalog are all original research drugs, reference preparations, passed consistency evaluation or new 4 types of drugs, and drugs included in the listing catalog set. It is necessary to pay attention to whether the provincial level continues the national requirements or is not Can those who have passed the evaluation participate in the competition?State Office [2021] No. 2 document once again mentioned that “if the number of generic drugs that have passed the consistency evaluation of online drugs exceeds 3, under the premise of ensuring supply, the centralized procurement will no longer select products that have not passed the consistency evaluation. "At present, there are only 2 companies in the national centralized procurement selection list with many varieties that have been reviewed. If the competition pattern remains the same after the centralized procurement expires, it is possible to introduce unreviewed varieties of the same dosage form, or introduce unreviewed varieties of other dosage forms. Varieties to purchase with quantity. In other words, if there is insufficient competition, it is possible to adopt a competitive approach.According to incomplete statistics, Heilongjiang, Shanxi, Xinjiang, Liaoning, Guizhou, Guangdong, Hubei and other places have all issued documents to renew the drug contracts related to the national centralized procurement expansion. As the expansion procurement period approaches, some selected companies will face Medical institutions revisited the issue of procurement volume. However, Inner Mongolia, Sichuan, Liaoning, Heilongjiang, etc. have not yet clarified the details of the renewal rules and did not produce renewal results. Therefore, the following is a comparison between the renewal rules of the Hebei Shanxi Alliance and the Guangdong Ten Provinces Alliance.Taking cephalexin as an example, the quality requirements and specifications of the second batch of centralized procurement renewal cephalexin are consistent with the product selected in the national centralized procurement by the Hebei Shanxi Alliance. The product required to be declared is only 0.25g of cephalexin oral dosage form.In addition to the oral regular-release dosage forms, the Guangdong Ten-province Alliance also included oral liquid, granules, effervescent tablets, and sustained-release controlled-release dosage forms for the second batch of centralized procurement renewal. Bigger. Regarding the quality requirements, oral regular-release dosage forms must be over-rated companies, and other dosage forms that have not been reviewed can also participate in the competition. Such a contract renewal program brings together the characteristics of centralized national procurement and local centralized procurement at the same time.


2. Purchase volume for renewal

(Take 0.25g of cephalexin oral normal-release dosage form as an example, the same below) The comparison between the agreed procurement volume of Hebei Shanxi and Guangdong Ten-province alliance and the national centralized procurement (unit: 10,000 pieces/piece).

It can be seen that Hebei’s contract has dropped slightly from last year, while Shanxi and Guangdong have both increased.


3. The renewal cycle

The renewal cycle and purchase volume will directly affect the company's bidding strategy. The longer the selection period, the more stable the market, and the shorter the selection period will also affect the enthusiasm of the company.

4, the declared price limit (oral regular-release dosage form 0.25g)

Guangdong did not carry out the price linkage with quantity, but borrowed the limit price for quantity purchase from Hebei and used it as its own limit price. The procurement volume of the Guangdong Ten-province Alliance is nearly three times that of Shanxi, Hebei, and the province’s price limit is taken over. If the volume of other provinces is less than the procurement volume of Hebei, how to limit the price? It is not yet known. 

5. Number of selected companies

The Hebei Shanxi Alliance and the Guangdong Ten-province Alliance both have exclusive selection requirements for the number of enterprises that are selected for oral regular-release dosage forms. Among them, the Guangdong Ten-province Alliance has introduced granular, effervescent, suspension and other dosage forms that are also exclusively selected. According to industry news, in the national centralized procurement, there are varieties selected from the original research. Most of the original researches select provinces with slightly underdeveloped economies, while the varieties selected in economically developed areas are mostly generic drugs. The primary reason is that the volume and price are linked, the exclusive choice is alternately selected provinces, the low price of generic drugs is selected, and the provinces with high volume are selected first, while the price of original drugs is high, and only provinces with low volume are selected. The second reason is that the original drugs are in The original market stock in developed areas is large, and even if it is not selected, a considerable stock will be retained and sold at the original price. Because of its good reputation among the patient masses, a large number of patients are still willing to use its medicines. In the end, low-priced generic drugs were selected in developed areas, while high-priced original research in areas with less economically underdeveloped areas were selected.

6, the selected price of the renewal

Is the selected price for national volume procurement the limit price for provincial renewal? In fact, it can be seen from the above that at least Hebei, Shanxi and the ten provinces of Guangdong are not restricted. In the end, Hebei Shanxi Province was selected for the renewal of the contract. The second batch of centralized procurement company North China Pharmaceutical Hebei Huamin Pharmaceutical Co., Ltd., the selected variety of cefalexin capsules 0.25g, the price is 0.1588 yuan / capsule. The Guangdong Ten-province Union renews the category 1 A purchase order, the selected variety is cephalexin capsules 0.25g, the price is 0.1489 yuan/capsule, the selected company is Hunan Kelun Pharmaceutical Co., Ltd.; the 2 category B purchase order is the cephalexin sustained-release tablet 0.25g, the price is 0.39 yuan/piece. The selected price of cephalexin capsules 0.25g has increased relative to the price of 0.081 yuan/capsule in the second batch of centralized procurement, instead of lowering the price as the main purpose. When the drug price returns to a reasonable range, the primary consideration is to ensure supply and price stability. , Appropriate price rise is conducive to the continuity of product supply. Looking at the renewal rules of various provinces, it can be said that a hundred flowers bloom, and the price of renewal can also be higher than the price selected last time, indicating that the marketization of drug prices has a great effect. Seeing such renewal prices and policy changes, relevant companies Will you be more actively involved in subsequent purchases with quantities? let us wait and see!